1900sek
-7,8 %
Date:2025-12-15Time:12:26:18Latest report:Q3-2025List:First NorthTicker:ANNX
Market Cap:134 msekEnterprise Value:97 msekNet Sales:- msekEarnings:-38,7 msekEmployees:0ISIN:SE0025159387

Ratios

10-year key figure history for Annexin turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Annexin with index and moving average MA50 and MA200.

Stockprice:19,00
MA50:25,18
MA200:28,85
Price/MA200:-34,1 %
RSI (14):17,4
Price/MA50:-24,5 %

Description

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Biotechnology